Compare · TGEN vs TMO
TGEN vs TMO
Side-by-side comparison of Tecogen Inc. (TGEN) and Thermo Fisher Scientific Inc (TMO): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both TGEN and TMO operate in Industrial Machinery/Components (Industrials), so they compete in similar markets.
- TMO is the larger of the two at $222.97B, about 2286.7x TGEN ($97.5M).
- TMO has been more active in the news (14 items in the past 4 weeks vs 12 for TGEN).
- TMO has more recent analyst coverage (25 ratings vs 4 for TGEN).
- Company
- Tecogen Inc.
- Thermo Fisher Scientific Inc
- Price
- -
- -
- Market cap
- $97.5M
- $222.97B
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Industrial Machinery/Components
- Industrial Machinery/Components
- Exchange
- AMEX
- NYSE
- IPO
- 2025
- News (4w)
- 12
- 14
- Recent ratings
- 4
- 25
Thermo Fisher Scientific Inc
Thermo Fisher Scientific Inc. offers life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and service worldwide. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets. Its Analytical Instruments segment provides instruments, consumables, software, and services for use in laboratory, on production line, and in field for pharmaceutical, biotechnology, academic, government, environmental, and other research and industrial markets, as well as clinical laboratories. The company's Specialty Diagnostics segment offers liquid, ready-to-use, and lyophilized immunodiagnostic reagent kits, as well as calibrators, controls, and calibration verification fluids; ImmunoCAP for allergy and asthma tests, and EliA for autoimmunity tests; dehydrated and prepared culture media, collection and transport systems, instrumentation, and consumables; human leukocyte antigen typing and testing for organ transplant market; and healthcare products. Its Laboratory Products and Services segment provides laboratory refrigerators and freezers, ultralow-temperature freezers, and cryopreservation storage tanks; temperature control, sample preparation and preservation, centrifugation, and biological safety cabinet products; water analysis instruments; laboratory plastics products; laboratory chemicals; and pharma services. The company offers products and services through a direct sales force, customer-service professionals, electronic commerce, third-party distributors, and catalogs. It has a strategic alliance with the University of California, San Francisco. The company was incorporated in 1956 and is based in Waltham, Massachusetts.
Latest TGEN
- Amendment: VP of Business Development Lafaille Stephen was granted 29,013 shares, increasing direct ownership by 234% to 41,389 units (SEC Form 4)
- Amendment: General Counsel & Secretary Whiting John Kimball Iv was granted 19,342 shares, increasing direct ownership by 86% to 41,954 units (SEC Form 4)
- Amendment: COO and President Panora Robert was granted 9,671 shares, increasing direct ownership by 15% to 72,194 units (SEC Form 4)
- Amendment: Chief Financial Officer Deschenes Roger P. was granted 29,013 shares, increasing direct ownership by 55% to 81,975 units (SEC Form 4)
- Amendment: Chief Executive Officer Rangesh Abinand was granted 174,081 shares, increasing direct ownership by 259% to 241,274 units (SEC Form 4)
- SEC Form 424B3 filed by Tecogen Inc.
- SEC Form EFFECT filed by Tecogen Inc.
- SEC Form EFFECT filed by Tecogen Inc.
- SEC Form POS AM filed by Tecogen Inc.
- SEC Form S-3 filed by Tecogen Inc.
Latest TMO
- Thermo Fisher upgraded by UBS with a new price target
- CLSA initiated coverage on Thermo Fisher with a new price target
- Executive Vice President Shafer Michael D covered exercise/tax liability with 790 shares, decreasing direct ownership by 4% to 20,204 units (SEC Form 4)
- SVP and General Counsel Shropshire Thomas B Jr. covered exercise/tax liability with 49 shares, decreasing direct ownership by 0.81% to 6,008 units (SEC Form 4)
- Sr. VP and Chief HR Officer Britt Lisa P. covered exercise/tax liability with 394 shares, decreasing direct ownership by 3% to 14,391 units (SEC Form 4)
- Sr. Vice President & CFO Meyer James covered exercise/tax liability with 270 shares, decreasing direct ownership by 5% to 5,560 units (SEC Form 4)
- Chairman & CEO Casper Marc N covered exercise/tax liability with 1,257 shares, decreasing direct ownership by 1% to 122,669 units (SEC Form 4)
- VP & Chief Accounting Officer Holmes Joseph R. covered exercise/tax liability with 50 shares, decreasing direct ownership by 2% to 2,916 units (SEC Form 4)
- President & COO Pettiti Gianluca covered exercise/tax liability with 1,035 shares, sold $2,539,233 worth of shares (4,133 units at $614.38) as part of a pre-agreed trading plan and exercised 3,733 shares at a strike of $309.63, decreasing direct ownership by 6% to 23,216 units (SEC Form 4)
- Thermo Fisher Scientific to Present at the Morgan Stanley 24th Annual Global Healthcare Conference on September 15, 2026